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ORIGINAL INVESTIGATIONSSGLT-2 Inhibitors and Cardiovascular Risk
An Analysis of CVD-REALMatthew A. Cavender, MD, MPH,a,b Anna Norhammar, MD,c Kåre I. Birkeland, MD,d Marit Eika Jørgensen, MD,e,f
John P. Wilding, MD,g Kamlesh Khunti, MD,h Alex Z. Fu, PHD,i Johan Bodegård, MD,j Betina T. Blak, PHD,k
Eric Wittbrodt, PHARMD, MPH,l Marcus Thuresson, PHD,m Peter Fenici, MD,n Niklas Hammar, PHD,c,o
Mikhail Kosiborod, MD,p on behalf of the CVD-REAL Investigators and Study GroupABSTRACTISS
Fro
cKa
Tra
fNaBACKGROUND Prior studies found patients treated with sodium-glucose co-transporter-2 inhibitors (SGLT-2i) had
lower rates of death and heart failure (HF). Whether the beneﬁts of SGLT-2i vary based upon the presence of
cardiovascular disease (CVD) is unknown.
OBJECTIVES This study sought to determine the association between initiation of SGLT-2i therapy and HF or death in
patients with and without CVD.
METHODS The CVD-REAL (Comparative Effectiveness of Cardiovascular Outcomes in New Users of SGLT-2 Inhibitors)
study was a multinational, observational study in which adults with type 2 diabetes were identiﬁed. Patients prescribed
an SGLT-2i or other glucose-lowering drugs (GLDs) were matched based on a propensity score for initiation of an
SGLT-2i. Hazard ratios (HRs) for the risk of death, HF, and HF or death in patients with and without established CVD were
estimated for each country and pooled.
RESULTS After propensity score matching, 153,078 patients were included in each group. At baseline, 13% had
established CVD. Compared with therapy using other GLDs, initiation of an SGLT-2i was associated with lower risk
of death in patients with and without CVD (HR: 0.56; 95% conﬁdence interval [CI]: 0.44 to 0.70; and HR: 0.56;
95% CI: 0.50 to 0.63, respectively). There were also associations between SGLT-2i and lower risk of HF (HR: 0.72;
95% CI: 0.63 to 0.82; and HR: 0.61; 95% CI: 0.48 to 0.78, respectively) and the composite of HF or death (HR:
0.63; 95% CI: 0.57 to 0.70; and HR: 0.56; 95% CI: 0.50 to 0.62, respectively) observed in patients with and
without established CVD.
CONCLUSIONS In this large, multinational, observational study, initiation of SGLT-2i was associated with lower risk
of death and HF regardless of pre-existing CVD. Ongoing clinical trials will provide further evidence regarding the
beneﬁt of SGLT-2i in patients without established CVD. (Comparative Effectiveness of Cardiovascular Outcomes in
New Users of SGLT-2 Inhibitors [CVD-REAL]; NCT02993614) (J Am Coll Cardiol 2018;71:2497–506) © 2018 The Authors.
Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).N 0735-1097 https://doi.org/10.1016/j.jacc.2018.01.085
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CVD = cardiovascular disease
GLD = glucose-lowering drug
HF = heart failure
SGLT-2i = sodium-glucose
co-transporter-2 inhibitors
T2D = type 2 diabetes
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2498P atients with type 2 diabetes (T2D) areat increased risk of cardiovasculardisease (CVD), including heart failure
(HF) and death (1,2). The EMPA-REG
OUTCOME (EMPAgliﬂozin Removal of Excess
of Glucose OUTCOME) trial was a random-
ized controlled trial of empagliﬂozin, a
sodium-glucose co-transporter-2 inhibitor
(SGLT-2i), in patients with T2D and estab-
lished CVD. In that trial, empagliﬂozinreduced the composite endpoint of cardiovascular
death, nonfatal myocardial infarction, or nonfatal
stroke. Furthermore, death and hospitalization for
HF were also reduced with empagliﬂozin (3). Direc-
tionally similar results for cardiovascular death or
HF were also seen in the CANVAS (CANagliﬂozin car-
dioVascular Assessment Study) program, which eval-
uated canagliﬂozin in 10,142 patients with T2D (4).
The CANVAS program included patients with and
without CVD at baseline; however, the majority of pa-
tients randomized into the program had established
CVD (5). These results were overall similar to the as-
sociation between SGLT-2i and major adverse cardio-
vascular events seen in registry-based data from
Sweden, Denmark, and Norway (6).SEE PAGE 2507The CVD-REAL (Comparative Effectiveness of
Cardiovascular Outcomes in New Users of SGLT-2
Inhibitors) study, an observational study that
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t received August 10, 2017; revised manuscript received January 1patients from 6 countries, found that initiation of
SGLT-2i therapy was associated with a signiﬁcantly
lower risk of death and HF than other glucose-
lowering drugs (GLDs) (7). However, whether these
relationships differ in patients with T2D based on the
presence of known CVD, particularly in the real-
world setting, remains unclear. Thus, in this anal-
ysis of the CVD-REAL study, we sought to determine
whether the associations among SGLT-2i, death, and
HF varied depending on the presence or absence of
CVD at the time of initiation of glucose-lowering
therapy.
METHODS
The CVD-REAL study (NCT02993614) design has pre-
viously been described in detail (7). For this particular
analysis, we used observational data from medical
records, medical claims, electronic health and death
records, and national registers collected from 5
countries (United States, United Kingdom, Sweden,
Norway, and Denmark) included in CVD-REAL. In the
United States, MarketScan Claims and Encounters
(Truven Health Analytics; IBM, Armonk, New York)
and linked Medicare Supplemental and Coordination
of Beneﬁts databases were used, which included
enrollment and demographic information, inpatient
and outpatient medical, and outpatient pharmacy
claims from >300 large, self-insured U.S. employers
and >25 U.S. health plans. Mortality data were
available from Truven Health Analytics (IBM) for aCentre, University of Leicester, Leicester, United
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2499proportion of patients in which information from the
Social Security Administration is integrated with the
insurance enrollment and claims data and supple-
mented by claims for in-hospital deaths (8). Charac-
teristics of U.S. patients with versus without linkage
to Social Security Administration data were previ-
ously demonstrated to be similar, indicating data
missing completely at random due to administrative
reasons. In Denmark, Norway, and Sweden, national
full-population registries were used that included all
medications, hospitalizations, and cause of death. In
the United Kingdom, the Clinical Practice Research
Datalink (CPRD) was used, which includes primary
care data from >670 general practices linked with
hospitalization and mortality registries (9), and The
Health Improvement Network (THIN) dataset, which
includes data from >580 U.K. practices, with primary
care data similar to those of CPRD (10). HF events
were uncommon in the dataset from Germany
(n ¼ 11), and data regarding death were not available;
therefore, we elected not to include data from Ger-
many in this particular analysis from the CVD-REAL
cohort.
Adult patients with T2D who had at least 1 year of
historical data available for analysis were eligible for
inclusion in the study. Patients known to have type 1
or gestational diabetes were excluded. Patients who
were newly initiated on either an SGLT-2i (canagli-
ﬂozin, dapagliﬂozin, or empagliﬂozin) or other GLDs
and did not have prescriptions for that particular
medication class within the prior year were identi-
ﬁed. Baseline characteristics of the patients prior to
the match have been published previously (7). A
nonparsimonious propensity score using variables
that might have affected treatment assignment or
outcomes was developed separately within each
country to predict the likelihood a patient would be
prescribed SGLT-2i (11–13). Candidate variables used
in the development of the propensity score have been
listed (Online Table 1). Patients in the 2 treatment
groups were matched 1:1 based on propensity scores.
For the matching in the United States and United
Kingdom, nearest neighbor caliper width of 0.25
multiplied by the SD of the propensity score distri-
bution was used (11), whereas an automated balance-
optimization method using function matching soft-
ware (R software: R Core Team, Vienna, Austria) and a
caliper of 0.2 were used for matching in Sweden,
Norway, and Denmark. Standardized differences of
post-matched patient characteristics were used to
assess the adequacy of propensity score matching,
where >10% standardized difference between the 2
groups after propensity score matching was consid-
ered a non-negligible imbalance (12).All analyses were performed using the intention-to-
treat principle in which patients were followed from
the time their therapy began (start date of the SGLT-2i
or other GLD ranged fromNovember 2012 in the United
Kingdom to July 2013 in Sweden) until they had a
cardiovascular event or were censored at the end of
follow-up (ranged from September 2015 in the United
States to November 2016 in Sweden). An on-treatment
analysis was also performed as a sensitivity analysis in
which patients were followed from the index date
until they either completed therapy with that partic-
ular drug, or died, or were censored at end of follow-
up. Patients were stratiﬁed based upon the presence
or absence of known CVD at the time when glucose-
lowering therapy was initiated. Patients were consid-
ered to have CVD if they had a prior history of acute
myocardial infarction, unstable angina, stroke, HF,
transient ischemic attack, coronary revascularization,
or occlusive peripheral artery disease.
The primary endpoints of interest were time to
death, HF, and composite endpoint of HF or death.
Hazard ratios (HRs) for each endpoint were estimated
for each country and then pooled using a random ef-
fects model with inverse variance weighting for each
country to generate a pooled HR and 95% conﬁdence
interval (CI) (14). HRs were adjusted for age, sex,
frailty (deﬁned as $1 hospital stay of $3 days within
1 year prior to the index date; deﬁned in the United
Kingdom as $1 hospital stay within 1 year prior to the
index date), history of myocardial infarction, history
of atrial ﬁbrillation, history of HF, hypertension,
obesity/body mass index, duration of GLD treatment
or diabetes, use of angiotensin-converting enzyme
inhibitor or angiotensin II receptor blockers, b-blocker
or a-blocker, calcium-channel blocker, loop diuretic,
aldosterone antagonist, or thiazide diuretic.
Analyses of de-identiﬁed data were conducted in
accordance with local laws and regulations and
received approvals from respective scientiﬁc/ethics/
data protection committees.
RESULTS
After propensity score matching, 306,156 patients
were included in the analysis (153,078 patients in
each treatment group). Baseline characteristics were
balanced between treatment groups in patients with
and without established CVD (Table 1). Most patients
in the propensity score-matched cohort did not have
established CVD; only 12.8% had a history of CVD, and
3.0% had a history of HF.
In the SGLT-2i group, of the total on-treatment
exposure time, 53.2% of patients received cana-
gliﬂozin, 41.4% received dapagliﬂozin, and 5.4%
TABLE 1 Baseline Characteristics
Cardiovascular Disease at Baseline No Cardiovascular Disease at Baseline
SGLT-2i
(n ¼ 19,529)
Other GLD
(n ¼ 19,764)
Standardized
Difference, %
SGLT-2i
(n ¼ 133,549)
Other GLD
(n ¼ 133,314)
Standardized
Difference, %
Age, yrs 62.7  9.7 63.5  10.4 8.3 56.0  9.8 56.0  10.5 0.6
Women 7,018 (35.9) 7,234 (36.6) 1.1 60,783 (45.5) 60,924 (45.7) 0.3
Duration of diabetes, yrs 8.7  4.4 9.1  4.5 9.2 7.6  4.3 7.7  4.4 4.3
History of CV disease* 19,529 (100.0) 19,764 (100.0) NA 0 (0.0) 0 (0.0) NA
AMI 3,651 (18.7) 3,733 (18.9) 0.4 0 (0.0) 0 (0.0) NA
Unstable angina 2,477 (12.7) 2,513 (12.7) 0.1 0 (0.0) 0 (0.0) NA
Heart failure 4,635 (23.7) 4,677 (23.7) 0.1 0 (0.0) 0 (0.0) NA
Atrial ﬁbrillation 2,721 (13.9) 2,854 (14.4) 1.2 2,835 (2.1) 2,765 (2.1) 0.3
Stroke 5,878 (30.1) 5,924 (30.0) 0.2 0 (0.0) 0 (0.0) NA
PAD 4,924 (25.2) 4,920 (24.9) 0.6 0 (0.0) 0 (0.0) NA
Microvascular disease 8,671 (44.4) 8,566 (43.3) 1.7 32,825 (24.6) 32,901 (24.7) 0.2
CKD 978 (5.0) 909 (4.6) 1.6 2,746 (2.1) 2,976 (2.2) 1.0
Frailty 5,130 (26.3) 5,413 (27.4) 2.1 7,015 (5.3) 7,102 (5.3) 0.3
Baseline glucose-lowering therapies
Metformin 14,690 (75.2) 15,740 (79.6) 8.5 105,778 (79.2) 106,647 (80.0) 1.6
Sulfonylurea 7,414 (38.0) 7,830 (39.6) 2.8 51,843 (38.8) 51,819 (38.9) 0.1
DPP-4i 6,214 (31.8) 6,423 (32.5) 1.2 44,728 (33.5) 43,184 (32.4) 1.9
Thiazolidinedione 1,305 (6.7) 1,295 (6.6) 0.4 12,336 (9.2) 11,670 (8.8) 1.4
GLP-1 RA 4,259 (21.8) 3,867 (19.6) 4.5 26,864 (20.1) 23,000 (17.3) 5.9
Insulin 7,695 (39.4) 7,645 (38.7) 1.2 37,163 (27.8) 36,748 (27.6) 0.5
Cardiovascular therapies
Antihypertensive therapy† 17,955 (91.9) 18,288 (92.5) 1.8 104,806 (78.5) 104,332 (78.3) 0.4
Loop diuretics 5,099 (26.1) 5,268 (26.7) 1.0 9,105 (6.8) 8,966 (6.7) 0.3
Thiazides 4,656 (23.8) 4,714 (23.9) 0.0 37,385 (28.0) 37,383 (28.0) 0.1
b-blockers 10,059 (51.5) 10,136 (51.3) 0.4 29,043 (21.7) 29,120 (21.8) 0.2
Calcium-channel blockers 6,396 (32.8) 6,635 (33.6) 1.4 29,525 (22.1) 29,445 (22.1) 0.0
Aldosterone antagonists 1,642 (8.4) 1,796 (9.1) 2.0 2,759 (2.1) 2,638 (2.0) 0.5
ACE inhibitors 9,119 (46.7) 9,351 (47.3) 1.0 57,258 (42.9) 57,352 (43.0) 0.2
ARBs 7,462 (38.2) 7,667 (38.8) 1.0 40,978 (30.7) 40,547 (30.4) 0.5
Statin therapy 15,852 (81.2) 16,211 (82.0) 1.8 87,560 (65.6) 87,355 (65.5) 0.1
Index year
2012 1 (0.0) 43 (0.5) 9.6 19 (0.1) 153 (0.6) 8.3
2013 2,760 (14.1) 3,006 (15.2) 2.5 18,369 (13.8) 22,554 (16.9) 7.3
2014 8,106 (41.5) 7,084 (35.8) 9.5 62,605 (46.9) 51,476 (38.6) 13.6
2015 7,982 (40.9) 9,045 (45.8) 8.1 50,478 (37.8) 56,900 (42.7) 8.2
2016 680 (8.2) 586 (6.9) 3.9 2,078 (7.5) 2,231 (8.1) 1.8
Values are mean  SD or n (%), unless otherwise stated. *Myocardial infarction, unstable angina, stroke, heart failure, transient ischemic attack, coronary revascularization,
or occlusive peripheral artery disease. †Includes ACE inhibitors, ARBs, calcium-channel blockers, b-blockers, and thiazides.
AMI ¼ acute myocardial infarction; ACE ¼ angiotensin-converting enzyme; ARB ¼ angiotensin II receptor blocker; CKD ¼ chronic kidney disease; CV ¼ cardiovascular;
DPP-4i ¼ dipeptidyl peptidase-4 inhibitor; GLP-1 RA ¼ glucagon-like peptide-1 receptor agonist; GLD ¼ glucose-lowering drug; PAD ¼ peripheral artery disease;
SGLT-2i ¼ sodium-glucose cotransporter-2 inhibitor.
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2500received empagliﬂozin. There was a signiﬁcant
amount of geographical variation with regard to
the speciﬁc SGLT-2i used. Canagliﬂozin was used
predominantly (75.9%) in the United States, and
dapagliﬂozin was used predominantly (92.2%) in
European countries (p < 0.001). Empagliﬂozin was
used infrequently in both the United States and in
Europe. In patients who began receiving other GLDs,
the most common classes were insulin (33.7%),
dipeptidyl peptidase-4 inhibitors (17.3%), sulfonyl-
ureas (17.1%), glucagon-like peptide-1 receptor
agonists (13.8%), and metformin (11.4%).The mean follow-up time ranged from 313 to
387 days in patients treated with SGLT-2i and from
299 to 383 days in patients treated with other GLDs.
There were 1,871 deaths and 1,586 HF events included
in the analysis. In patients with established CVD, the
death rate was 2.7 per 100 person-years, and the HF
rate was 2.7 per 100 patient-years; whereas in pa-
tients without established CVD, the death rate was 0.7
per 100 person-years, and the HF rate was 0.2 per 100
patient-years (Figure 1).
Patients treated with SGLT-2i, including those with
and without established CVD, had lower absolute
FIGURE 1 Event Rates Following Initiation of Glucose-Lowering Therapy in Patients
With and Without Cardiovascular Disease
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2501rates of HF, death, and HF or death than patients
taking other GLDs (Figure 2, Online Table 2).
Compared to other GLDs, the use of SGLT-2i was
associated with lower risk of death in both patients
with and without CVD (1.8 vs. 3.6 events per 100
patient-years, respectively; HR: 0.56; 95% CI: 0.44 to
0.70; and 0.5 vs. 0.9 events per 100 patient-years,
respectively; HR: 0.56; 95% CI: 0.50 to 0.63). There
was no signiﬁcant geographical heterogeneity in this
association among patients with or without CVD
(p ¼ 0.06 and p ¼ 0.56, respectively). Compared with
other GLDs, SGLT-2i were also associated with lower
risk of HF in both subgroups (2.3 vs. 3.2 events per
100 patient-years, respectively; HR: 0.72; 95% CI: 0.63
to 0.82; and 0.1 vs. 0.2 events per 100 patient-years,
respectively; HR: 0.61; 95% CI: 0.48 to 0.78) (Central
Illustration). When we evaluated these endpoints as
a composite, the overall relationship persisted, and
use of SGLT-2i, compared with other GLDs, was
associated with lower risk of the composite endpoint
of death or HF in patients with and without CVD (4.0
vs. 6.7 events per 100 patient years, respectively;
HR: 0.63; 95% CI: 0.57 to 0.70; and 0.6 vs. 1.1 events
per 100 patient years, respectively; HR: 0.56; 95%
CI: 0.50 to 0.62) (Figure 3). Similar ﬁndings were seen
when limiting the analyses to a cohort that was on-
treatment (Online Figures 1 and 2). As a further
sensitivity analysis using data from Sweden and
Norway, separate propensity scores were developed
speciﬁcally in the cohorts with and without estab-
lished cardiovascular disease, and the results were
consistent with the overall ﬁndings (Online Table 3,
Online Figures 3 and 4).
In order to determine the possibility of unmea-
sured residual confounding despite propensity score
matching, we evaluated a negative control. In the
Marketscan (Truven Health Analytics; IBM) dataset
from the United States, there were 219 occurrences of
atrial ﬁbrillation in the on-treatment analysis. There
was no association between initiation of SGLT-2i and
other GLDs and the onset of atrial ﬁbrillation (HR:
0.96; 95% CI: 0.73 to 1.25).
DISCUSSION
In this observational analysis of the CVD-REAL study,
which included >300,000 patients from 5 countries,
the following important ﬁndings are noted. First,
most patients treated with SGLT-2i in clinical practice
during the course of this study did not have an
established history of CVD. Second, we found an as-
sociation between the use of SGLT-2i and a lower risk
of death and HF that was observed across the spec-
trum of risk including patients with and withoutestablished CVD. This association provides supports
for the beneﬁt of SGLT-2i, particularly with regard to
HF, that were seen in 2 prior trials. As such, our
ﬁndings suggest that the beneﬁts seen in clinical tri-
als may extend to patients treated with SGLT-2i as
part of clinical practice (15). In this analysis, we pre-
sent stratiﬁed data suggesting a similar association
(from a relative risk standpoint) in patients with and
without established CVD; thus, it is possible the
beneﬁts of SGLT-2i could extend to a broad popula-
tion of patients with T2D. This is especially important
given that patients with diabetes are typically risk
stratiﬁed using only clinical variables and history,
such as the presence of a prior cardiovascular event,
although this may not be the best strategy to identify
those patients who are at highest risk for future car-
diovascular events (16,17).
The relative risk of the associations among SGLT-2i
and HF and death seen in the CVD-REAL study were
similar in patients with and without established CVD.
However, the absolute event rates which we observed
suggest that the number needed to treat (in a hypo-
thetical randomized controlled trial) would likely be
substantially greater in patients without established
CVD than in those with CVD. Conversely, the number
needed to treat would be expected to be lower in the
subgroup with known CVD (18).
The association between SGLT-2i and outcomes
seen in CVD-REAL was directionally consistent across
the different countries included in the analysis.
FIGURE 2 Event Rates Following Initiation of Glucose-Lowering Therapy in Patients With and Without Cardiovascular Disease Stratiﬁed
by Treatment With Sodium-Glucose Co-Transporter-2 Inhibitors or Other Glucose-Lowering Drugs
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2502Despite considerable variation in the speciﬁc SGLT-2i
used in the United States and Europe, there was no
geographic heterogeneity in the associations between
initiation of SGLT-2i (versus other glucose-lowering
agents) and events of HF and death (19–21). These
ﬁndings provide indirect evidence for the possibility
that SGLT-2 inhibition, regardless of the particular
agent, is associated with lower risk of death or HF (22).
It is important to consider these ﬁndings in the
context of randomized controlled trials of SGLT-2i.
The EMPA-REG trial showed that treatment with
empagliﬂozin in patients with established CVD
signiﬁcantly reduced major adverse cardiovascular
events, deﬁned as cardiovascular death, myocardial
infarction, and stroke (3). Empagliﬂozin was also
shown to reduce the risk of death (HR: 0.68) and
hospitalization for HF (HR: 0.65). All patients ran-
domized in the EMPA-REG trial had established CVD,
providing strong evidence for cardiovascular beneﬁt
in this population; however, the effects of empagli-
ﬂozin in patients without established CVD remain
unknown.The CANVAS program included results from 2
separate studies that had similar inclusion criteria
and data collection processes. In the integrated
analysis of the CANVAS program, most patients had
known CVD, but approximately 30% of the combined
population was at increased risk for cardiovascular
events and no history of CVD. In those trials, patients
with established CVD at baseline had a statistically
signiﬁcant reduction in the primary endpoint of time
to cardiovascular death, myocardial infarction, or
stroke, whereas there was no statistically signiﬁcant
reduction seen in the subgroup without established
CVD (HR: 0.98; 95% CI: 0.74 to 1.30) (5). However, the
CANVAS program was not powered for superiority of
the primary endpoint of major adverse cardiac
event(s) within each of these subgroups, and there
was no statistical evidence of heterogeneity in the
effect of canagliﬂozin by the presence of established
CVD (p [heterogeneity] ¼ 0.18). Furthermore, the ef-
fects of canagliﬂozin on death and HF were similar in
the subgroups of patients with and without CVD (23).
As such, these data, in conjunction with this
CENTRAL ILLUSTRATION Sodium-Glucose Co-Transporter-2 Inhibitors in Patients With and Without
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2503observational data, support the hypothesis that the
presence of established CVD is not an effect modiﬁer
for the efﬁcacy of SGLT-2i with regard to HF and
death, and provide cardiovascular beneﬁt in patients
without established CVD (24).
The DECLARE-TIMI 58 (Multicenter Trial to Eval-
uate the Effect of Dapagliﬂozin on the Incidence of
Cardiovascular Events) trial is currently ongoing and
is testing the efﬁcacy of dapagliﬂozin in patients with
either established CVD or with risk factors for CVD
(25). The co-primary efﬁcacy endpoint of this trial is
cardiovascular death or HF, similar to the endpoints
evaluated in our CVD-REAL study. Most patients
randomized in DECLARE-TIMI 58 do not have estab-
lished CVD (26). Thus, that trial will provide impor-
tant additional data regarding the effectiveness of
SGLT-2i in patients without established CVD (27).
Nevertheless, it is important to consider that patients
without CVD included in randomized trials still
represent a higher risk cohort, due to inclusion
criteria requiring presence of CV risk factors, than
those without CVD in the CVD-REAL study. It is un-
likely, therefore, that the type of “primary preven-
tion” patients we evaluated in this analysis would
ever be included in a future clinical trial, and largepopulation-based studies such as CVD-REAL may
represent the only opportunity to better understand
potential cardiovascular effects associated with
SGLT-2i in this group.
STUDY LIMITATIONS. Our ﬁndings should be
considered in the context of several potential limita-
tions. First, due to the observational nature of these
analyses, the possibility of residual, unmeasured
confounding cannot be eliminated, despite the use of
a robust (nonparsimonious) propensity score match-
ing and additional statistical adjustments. While the
fact that there was no evidence of association
between SGLT-2i and a negative control provides
support for the robustness of the association between
SGLT-2i and lower rates of HF and death, this
does not completely eliminate the possibility of
residual confounding. In this analysis, we used a
propensity score developed within each country for
the overall cohort based on the data and variables
collected within that speciﬁc country, outcomes were
then evaluated in the subgroups of patients with
and without established CVD. Subgroup-speciﬁc
propensity scores in patients with and without
established CVD were not developed to prevent
FIGURE 3 Adjusted Hazard Ratios for Heart Failure or Death
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2504introducing instability into the point estimates,
which could occur if one were to develop propensity
scores that were both country- and subgroup-speciﬁc.
However, when such subgroup-speciﬁc scores were
developed in Sweden and Norway, the results were
highly consistent. Several ongoing clinical trials in
patients with T2D and a range of CVD risk are pres-
ently testing the effects of SGLT-2i on cardiovascular
events and will provide considerable insight into
these potential beneﬁts, including efﬁcacy in
important subgroups (DECLARE [NCT01730534] and
VERTIS [Cardiovascular Outcomes Following Ertu-
gliﬂozin Treatment in Type 2 Diabetes MellitusParticipants With Vascular Disease; NCT01986881]
trials) (25,28). Second, although the current study
included many patient-years of follow-up, use of
SGLT-2i in clinical practice is limited; thus, additional
follow-up would be useful to better understand
whether the effects associated with SGLT-2i are sus-
tained over time. Third, we were unable to assess for
adverse effects including the risk of amputation as
seen in a recent randomized clinical trial with an
SGLT-2i. Finally, mortality may not be completely
captured in the Truven Health Analytics (IBM) dataset
due to changes in the acquisition of data in the death
master ﬁle, which is one source of mortality data in
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: In a large
multinational population of patients with T2D from Europe and
North America, treatment with SGLT-2i was associated with
lower rates of death and HF regardless of the presence of
established cardiovascular disease. These data suggest that the
beneﬁt from SGLT-2i could extend across the continuum of
cardiovascular risk.
TRANSLATIONAL OUTLOOK: Further studies are needed to
clarify the mechanisms by which SGLT-2i reduce cardiovascular
events.
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2505the United States. However, this would not be ex-
pected to affect the overall associations between
SGLT-2i and death, as any missing mortality data
would occur completely at random, due to adminis-
trative reasons (8). This is supported by the ﬁnding of
similar associations between SGLT-2i use and death
across the different geographic areas.
CONCLUSIONS
In this observational analysis of the CVD-REAL study,
most patients treated with SGLT-2i in clinical practice
across 5 countries do not have established CVD. Pa-
tients with and without established CVD are at lower
associated risk of both death and HF after initiation of
SGLT-2i therapy compared to therapy with other
GLDs. Although long-term follow-up data from
observational studies such as CVD-REAL and ongoing
randomized clinical trials are needed to fully under-
stand whether the effects of SGLT-2i are sustained
over time, these ﬁndings suggest that the cardiovas-
cular beneﬁts of SGLT-2i may not be speciﬁc to a
single compound, and may extend to a broader pop-
ulation of patients with T2D than previously consid-
ered. Data from ongoing randomized clinical trials
will provide further evidence regarding the cardio-
vascular beneﬁts of different SGLT-2i, including in
patients without established CVD.
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